Why the growth investor may take a look at NASDAQ:ARCT.

In this article we will dive into ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) as a possible candidate for growth investing. Investors should always do their own research, but we noticed ARCTURUS THERAPEUTICS HOLDIN showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

What matters for growth investors.

• ARCTURUS THERAPEUTICS HOLDIN exhibits a strong Return on Equity (ROE) of 35.45%, indicating the company's ability to generate solid returns on shareholder investments. This metric reflects the company's efficient utilization of equity capital and its profitability.
• With a track record of beating EPS estimates 3 times in the last 4 quarters, ARCTURUS THERAPEUTICS HOLDIN showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
• With impressive 1-year revenue growth of 475.0%, ARCTURUS THERAPEUTICS HOLDIN showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
• ARCTURUS THERAPEUTICS HOLDIN has demonstrated strong quarter-to-quarter (Q2Q) revenue growth of 237.0%, reflecting its ability to generate consistent increases in sales. This growth highlights the company's effective market positioning and its potential for continued success.
• The operating margin of ARCTURUS THERAPEUTICS HOLDIN has seen steady growth over the past year, signaling improved profitability. This trend indicates the company's effective cost management and its ability to generate higher returns.
• ARCTURUS THERAPEUTICS HOLDIN has shown positive growth in its free cash flow (FCF) over the past year, indicating improved cash generation and financial strength. This growth highlights the company's ability to effectively manage its cash flows and generate surplus funds.
• ARCTURUS THERAPEUTICS HOLDIN has demonstrated consistent growth in its earnings per share (EPS) from one quarter to another (Q2Q), with a 54.14% increase. This indicates improving financial performance and the company's effective management of its operations.
• ARCTURUS THERAPEUTICS HOLDIN has seen a 20.5% change in the average next Quarter EPS Estimate by analysts over the last 3 months, signaling the shifting perception of the company's EPS outlook.
• The recent financial report of ARCTURUS THERAPEUTICS HOLDIN demonstrates a 54.14% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• ARCTURUS THERAPEUTICS HOLDIN shows accelerating EPS growth: when comparing the current Q2Q growth of 54.14% to the previous year Q2Q growth of 35.12%, we see the growth rate improving.

Fundamental Analysis Observations

Every day ChartMill assigns a Fundamental Rating to every stock. The score ranges from 0 to 10 and is determined by evaluating multiple fundamental indicators and properties.

We assign a fundamental rating of 6 out of 10 to ARCT. ARCT was compared to 610 industry peers in the Biotechnology industry. ARCT has an excellent financial health rating, but there are some minor concerns on its profitability. ARCT is not priced too expensively while it is growing strongly. Keep and eye on this one!

For an up to date full fundamental analysis you can check the fundamental report of ARCT

More growth stocks can be found in our Lois Navellier screen.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.